A BBB-penetrant nanotherapy (OAMs) combining zwitterionic OPDEA micelles with artesunate suppresses HMOX1-mediated ferroptosis, restores iron homeostasis, and provides neuroprotection after cardiac arrest and cardiopulmonary resuscitation.
Key Findings
Results
Zwitterionic poly(tertiary amine oxide)-based micelles (OPDEA) loaded with artesunate (OAMs) efficiently cross the intact blood-brain barrier via adsorptive-mediated transcytosis.
The nanoformulation uses zwitterionic OPDEA polymer as the carrier material combined with the pleiotropic neuroprotectant artesunate (Art).
BBB penetration was achieved through adsorptive-mediated transcytosis, a mechanism that does not require receptor-mediated uptake.
OAMs accumulated specifically in hippocampal neurons and microglia following systemic administration.
Penetration was demonstrated across an intact BBB, which is a key barrier for post-resuscitation drug delivery.
Results
HMOX1-mediated ferroptosis was identified as a key mechanism of post-resuscitation neuronal injury in both in vitro and in vivo models.
This finding was established using in vitro hypoxia-reoxygenation models and in vivo male mouse cardiac arrest/CPR models.
HMOX1 (haem oxygenase-1) activity was identified as a driver of ferroptotic cell death following ischaemia-reperfusion injury.
The HMOX1-ferroptosis axis was described as 'a tractable therapeutic target' for post-resuscitation neuroprotection.
Ferroptosis, an iron-dependent form of regulated cell death involving lipid peroxidation, was mechanistically linked to HMOX1 dysregulation after cardiac arrest.
Results
OAMs suppressed HMOX1 activity and restored iron homeostasis following cardiac arrest and resuscitation.
Treatment with OAMs reduced HMOX1 enzymatic activity in the post-resuscitation brain.
Restoration of iron homeostasis was demonstrated as a downstream consequence of HMOX1 suppression.
Dysregulated iron metabolism driven by HMOX1 was identified as a proximal cause of ferroptotic neuronal death.
These effects were observed in the context of global ischaemia-reperfusion injury induced by cardiac arrest.
Results
OAMs alleviated lipid peroxidation and preserved mitochondrial function and neuronal viability after ischaemia-reperfusion injury.
Reduction in lipid peroxidation was demonstrated following OAM treatment, consistent with ferroptosis inhibition.
Mitochondrial function was preserved in neurons treated with OAMs compared to untreated controls.
Neuronal viability was maintained following OAM treatment in both hypoxia-reoxygenation and CA/CPR models.
These functional outcomes downstream of HMOX1 suppression and iron homeostasis restoration collectively define the neuroprotective mechanism.
Background
Cardiac arrest induces global ischaemia-reperfusion injury associated with extensive neuronal damage, high mortality, and cognitive impairment, for which effective neuroprotective therapies are lacking.
The study framed CA-induced global I/R injury as a major unmet clinical need with high rates of mortality and cognitive impairment.
The BBB was identified as 'a major barrier to intervention' that restricts drug access to injured brain tissue.
Existing neuroprotective approaches were described as insufficient, motivating development of the BBB-penetrant nanotherapy.
Male mice were used as the in vivo model for CA/CPR experiments.
Conclusions
OPDEA micelles are positioned as a BBB-penetrant nanoplatform applicable beyond cardiac arrest to other central nervous system diseases.
The authors suggest OPDEA micelles could serve as a general CNS drug delivery platform beyond post-resuscitation neuroprotection.
The zwitterionic poly(tertiary amine oxide) chemistry was highlighted as a key design feature enabling BBB penetration.
The platform's applicability to 'other central nervous system diseases' was noted as a broader implication of this work.
Artesunate was characterized as a 'pleiotropic neuroprotectant,' suggesting multiple mechanisms of action beyond HMOX1 suppression.
What This Means
When someone suffers a cardiac arrest, the interruption of blood flow followed by its restoration (ischaemia-reperfusion injury) causes widespread brain damage. One major reason treatments fail is that the brain is protected by a tightly sealed barrier — the blood-brain barrier — that blocks most drugs from entering. This research describes a new nanoparticle drug delivery system called OAMs, made from a special zwitterionic polymer (OPDEA) loaded with an existing drug called artesunate, that can cross this barrier and reach injured brain cells. The nanoparticles get into the brain through a natural transport process called adsorptive-mediated transcytosis and accumulate in the types of brain cells most vulnerable to cardiac arrest injury.
The study also identified a previously underappreciated mechanism of brain cell death after cardiac arrest: a protein called HMOX1 (haem oxygenase-1) drives a type of iron-dependent cell death called ferroptosis, which involves toxic lipid damage and mitochondrial dysfunction. The OAM nanoparticles suppressed HMOX1 activity, restored normal iron balance in brain cells, reduced lipid damage, and kept mitochondria functioning — collectively protecting neurons from dying after simulated cardiac arrest in both cell culture and mouse models.
This research suggests that the HMOX1-ferroptosis pathway is an important and targetable cause of brain injury after cardiac arrest, and that specially engineered nanoparticles can deliver protective drugs across the blood-brain barrier to address it. Beyond cardiac arrest, the OPDEA micelle platform may be adaptable for treating other brain diseases where drug delivery across the blood-brain barrier is a challenge.